Abstract/References

Since 2000, rapid antigen detection kits and anti-influenza drugs have been used for the early diagnosis and treatment of influenza in Japan, respectively.　The main drugs available in clinical practice are the neuraminidase inhibitors oseltamivir, zanamivir, laninamivir, and peramivir, as well as the cap-dependent endonuclease inhibitor baloxavir marboxil.　Antiviral therapy with neuraminidase inhibitors has been practiced for many years, especially in Japan; it can shorten the febrile period and reduce complications.　Despite having similar structures, the pharmacologic background of neuraminidase inhibitors differs significantly, as reflected in their varying clinical efficacy.　Due to its inhibitory mechanism, baloxavir marboxil can rapidly reduce the viral load than neuraminidase inhibitors.　However, the duration of symptoms was similar after the administration of baloxavir marboxil and oseltamivir, and variants with reduced drug susceptibility have been detected in 20%–30% of pediatric patients treated with baloxavir marboxil.　Clinical trials of several novel anti-influenza drugs are currently underway.　When these drugs are first marketed, the characteristics of the influenza virus and the pharmacologic background of the drugs must be clarified before their administration to patients in clinical practice.

1. Wright PF, Neumann G, Kawaoka Y:Orthomyxoviruses.　In Knipe DM, Howley PM, eds:Fields Virology.　6th ed.　Lippincott Williams & Wilkins, Philadelphia, 1186-1243, 2013.

2. Hause BM, Collin EA, Liu R, et al.　Characterization of a novel influenza virus in cattle and Swine:proposal for a new genus in the Orthomyxoviridae family.　mBio, 5:e00031-14, 2014.

3. Kwasnik M, Rola J, Rozek W.　Influenza D in domestic and wild animals.　Viruses, 15:2433, 2023.

4. Heldt FS, Frensing T, Reichl U.　Modeling the intracellular dynamics of influenza virus replication to understand the control of viral RNA synthesis.　J Virol, 86:7806-7817, 2012.

5. Baccam P, Beauchemin C, Macken CA, Hayden FG, Perelson AS.　Kinetics of influenza A virus infection in humans.　J Virol, 80:7590-7599, 2006.

6. Bright RA, Shay DK, Shu B, Cox NJ, Klimov AI.　Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States.　JAMA, 295:891-894, 2006.

7. Meindl P, Bodo G, Palese P, Schulman J, Tuppy H.　Inhibition of neuraminidase activity by derivatives of 2-deoxy-2,3-dehydro-N-acetylneuraminic acid.　Virology, 58:457-463, 1974.

8. Li W, Escarpe PA, Eisenberg EJ, et al.　Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071.　Antimicrob Agents Chemother, 42:647-653, 1998.

9. Oo C, Barrett J, Hill G, et al.　Pharmacokinetics and dosage recommendations for an oseltamivir oral suspension for the treatment of influenza in children.　Paediatr Drugs, 3:229-236, 2001.

10. Oo C, Hill G, Dorr A, Liu B, Boellner S, Ward P.　Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1-5 years.　Eur J Clin Pharmacol, 59:411-415, 2003.

11. Pharmaceuticals and Medical Devices Agency.　Tamiflu 3% dry syrup (in Japanese).　https://www.info.pmda.go.jp/go/pack/6250021R1024_1_30/.　Accessed at 2024/04/01

12. Eisenberg EJ, Bidgood A, Cundy KC.　Penetration of GS4071, a novel influenza neuraminidase inhibitor, into rat bronchoalveolar lining fluid following oral administration of the prodrug GS4104.　Antimicrob Agents Chemother, 41:1949-1952, 1997.

13. Wattanagoon Y, Stepniewska K, Lindegårdh N, et al.　Pharmacokinetics of high-dose oseltamivir in healthy volunteers.　Antimicrob Agents Chemother, 53:945-952, 2009.

14. Okomo-Adhiambo M, Sleeman K, Lysén C, et al.　Neuraminidase inhibitor susceptibility surveillance of influenza viruses circulating worldwide during the 2011 Southern Hemisphere season.　Influenza Other Respir Viruses, 7:645-658, 2013.

15. Treanor JJ, Hayden FG, Vrooman PS, et al.　Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza:a randomized controlled trial.　US Oral Neuraminidase Study Group.　JAMA, 283:1016-1024, 2000.

16. Muthuri SG, Venkatesan S, Myles PR, et al.　Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection:a meta-analysis of individual participant data.　Lancet Respir Med, 2:395-404, 2014.

17. Whitley RJ, Hayden FG, Reisinger KS, et al.　Oral oseltamivir treatment of influenza in children.　Pediatr Infect Dis J, 20:127-133, 2001.

18. Coffin SE, Leckerman K, Keren R, Hall M, Localio R, Zaoutis T.　Oseltamivir shortens hospital stays of critically ill children hospitalized with seasonal influenza:a retrospective cohort study.　Pediatr Infect Dis J, 30:962-966, 2011.

19. Sato M, Hosoya M, Kato K, Suzuki H.　Viral shedding in children with influenza virus infections treated with neuraminidase inhibitors.　Pediatr Infect Dis J, 24:931-932, 2005.

20. Sugaya N, Mitamura K, Yamazaki M, et al.　Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children.　Clin Infect Dis, 44:197-202, 2007.

21. Kawai N, Ikematsu H, Iwaki N, et al.　Comparison of the effectiveness of Zanamivir and Oseltamivir against influenza A/H1N1, A/H3N2, and B.　Clin Infect Dis, 48:996-997, 2009.

22. Dominiak PM, Volkov A, Dominiak AP, Jarzembska KN, Coppens P.　Combining crystallographic information and an aspherical-atom data bank in the evaluation of the electrostatic interaction energy in an enzyme-substrate complex:influenza neuraminidase inhibition.　Acta Crystallogr D, 65:485-499, 2009.

23. Stoll V, Stewart KD, Maring CJ, et al.　Influenza neuraminidase inhibitors:structure-based design of a novel inhibitor series.　Biochemistry, 42:718-727, 2003.

24. Laver WG, Bischofberger N, Webster RG.　Disarming flu viruses.　Sci Am, 280:78-87, 1999.

25. Lew W, Chen X, Kim CU.　Discovery and development of GS 4104 (oseltamivir) an orally active influenza neuraminidase inhibitor.　Curr Med Chem, 7:663-672, 2000.

26. Gubareva LV, Kaiser L, Hayden FG.　Influenza virus neuraminidase inhibitors.　Lancet, 355:827-835, 2000.

27. Hedrick JA, Barzilai A, Behre U, et al.　Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age:a randomized controlled trial.　Pediatr Infect Dis J, 19:410-417, 2000.

28. Koyama K, Takahashi M, Oitate M, et al.　CS-8958, a prodrug of the novel neuraminidase inhibitor R-125489, demonstrates a favorable long-retention profile in the mouse respiratory tract.　Antimicrob Agents Chemother, 53:4845-4851, 2009.

29. Watanabe A, Chang SC, Kim MJ, Chu DW, Ohashi Y, MARVEL Study Group.　Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza:a double-blind, randomized, noninferiority clinical trial.　Clin Infect Dis, 51:1167-1175, 2010.

30. Watanabe A.　A randomized double-blind controlled study of laninamivir compared with oseltamivir for the treatment of influenza in patients with chronic respiratory diseases.　J Infect Chemother, 19:89-97, 2013

31. Sugaya N, Ohashi Y.　Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection.　Antimicrob Agents Chemother, 54:2575-2582, 2010.

32. GlobeNewswire:Biota Reports Top-Line Data From Its Phase 2 “IGLOO” Trial of Laninamivir Octanoate.　https://www.globenewswire.com/news-release/2014/08/01/655382/10092476/en/Biota-Reports-Top-Line-Data-From-Its-Phase-2-IGLOO-Trial-of-Laninamivir-Octanoate.html.　Accessed at 2024/08/21.

33. Katsumi Y, Otabe O, Matsui F, et al.　Effect of a single inhalation of laninamivir octanoate in children with influenza.　Pediatrics 129;e1431-e1436, 2012.

34. Koseki N, Kaiho M, Kikuta H, et al.　Comparison of the clinical effectiveness of zanamivir and laninamivir octanoate for children with influenza A(H3N2) and B in the 2011-2012 season.　Influenza Other Respir Viruses, 8:151-158, 2014.

35. Pharmaceuticals and Medical Devices Agency.　Rapiacta (in Japanese).　https://www.info.pmda.go.jp/go/interview/1/340018_6250405A1032_1_011_1F.pdf.　Accessed at 2024/04/01

36. Funatsu Y, Tasaka S, Asami T, et al.　Pharmacokinetics of intravenous peramivir in the airway epithelial lining fluid of healthy volunteers.　Antivir Ther, 21:621-625, 2016.

37. Kohno S, Kida H, Mizuguchi M, Shimada J, S-021812 Clinical Study Group.　S-021812 Clinical Study Group.　Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.　Antimicrob Agents Chemother, 54:4568-4574, 2010.

38. Ison MG, Hui DS, Clezy K, et al.　A clinical trial of intravenous peramivir compared with oral oseltamivir for the treatment of seasonal influenza in hospitalized adults.　Antivir Ther, 18:651-661, 2013.

39. Sato M, Ito M, Suzuki S, et al.　Influenza viral load and peramivir kinetics after single administration and proposal of regimens for peramivir administration against resistant variants.　Antimicrob Agents Chemother, 59:1643-1649, 2015.

40. Sugaya N, Kohno S, Ishibashi T, Wajima T, Takahashi T.　Efficacy, safety, and pharmacokinetics of intravenous peramivir in children with 2009 pandemic H1N1 influenza A virus infection.　Antimicrob Agents Chemother, 56:369-377, 2012.

41. Sato M, Honzumi K, Sato T, et al.　Quantitative analysis of influenza A (H3N2) E119V and R292K variants in clinical specimens by real-time reverse transcription polymerase chain reaction.　J Clin Virol, 68:97-103, 2015.

42. Matsuo Y, Ishibashi T, Hollister AS, Wajima T.　Population pharmacokinetics of peramivir in healthy volunteers and influenza patients.　Antimicrob Agents Chemother, 59:6755-6762, 2015.

43. Noshi T, Kitano M, Taniguchi K, et al.　In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit.　Antiviral Res, 160:109-117, 2018.

44. Hayden FG, Sugaya N, Hirotsu N, et al.　Baloxavir marboxil for uncomplicated influenza in adults and adolescents.　N Engl J Med, 379:913-923, 2018.

45. Ikematsu H, Hayden FG, Kawaguchi K, et al.　Baloxavir marboxil for prophylaxis against influenza in household contacts.　N Engl J Med, 383:309-320, 2020.

46. Hirotsu N, Sakaguchi H, Sato C, et al.　Baloxavir marboxil in Japanese pediatric patients with influenza:safety and clinical and virologic outcomes.　Clin Infect Dis, 71:971-981, 2020.

47. Sato M, Takashita E, Katayose M, et al.　Detection of variants with reduced baloxavir marboxil susceptibility after treatment of children with influenza A during the 2018-2019 influenza season.　J Infect Dis, 222:121-125, 2020.

48. Sato M, Takashita E, Katayose M, et al.　Detection of variants with reduced baloxavir marboxil and oseltamivir susceptibility in children with influenza A during the 2019-2020 influenza season.　J Infect Dis, 224:1735–1741, 2021.

49. Takashita E, Ejima M, Itoh R, et al.　A community cluster of influenza A(H1N1) pdm09 virus exhibiting cross-resistance to oseltamivir and peramivir in Japan, November to December 2013.　Euro Surveill, 19:p. 20666, 2014.

50. Meijer A, Rebelo-de-Andrade H, Correia V, et al.　Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012-2013.　Antiviral Res, 110:31-41, 2014.

51. Roosenhoff R, Reed V, Kenwright A, et al.　Viral kinetics and resistance development in children treated with neuraminidase inhibitors:the influenza resistance information study (IRIS).　Clin Infect Dis, 71:1186-1194, 2020.

52. Uehara T, Hayden FG, Kawaguchi K, et al.　Treatment-emergent influenza variant viruses with reduced baloxavir susceptibility:impact on clinical and virologic outcomes in uncomplicated influenza.　J Infect Dis, 221:346-355, 2020.

53. Yokoyama T, Sakaguchi H, Ishibashi T, et al.　Baloxavir marboxil 2% granules in Japanese children with influenza:an open-label phase 3 study.　Pediatr Infect Dis J, 39:706-712, 2020.

54. Baker J, Block SL, Matharu B, et al.　Baloxavir marboxil single-dose treatment in influenza-infected children:a randomized, double-blind, active controlled phase 3 safety and efficacy trial (miniSTONE-2).　Pediatr Infect Dis J, 39:700-705, 2020.

55. Sonoyama T, Sakaguchi H, Koshimichi H, Noshi T, Tsuchiya K, Uehara T.　Open-label study of the safety, pharmacokinetics, and effectiveness of a 2 mg/kg dose of baloxavir marboxil 2% granules in children <20 kg with influenza.　J Infect Chemother, 27:1223-1229, 2021.

56. Japan Pediatric Society.　Influenza treatment and prevention guidelines for the 2023/24 season (in Japanese).　https://www.jpeds.or.jp/uploads/files/20231122_influenza.pdf.　Accessed at 2024/04/10

57. Japanese Association for Infectious Diseases.　New recommendations for the use of the cap-dependent endonuclease inhibitor baloxavir marboxil (Zofluza®) (revised Nov. 27, 2023) (in Japanese).　https://www.kansensho.or.jp/modules/guidelines/index.php?content_id=52.　Accessed at 2024/04/10

58. Sato M, Honzumi K, Sato T, et al.　Sequential influenza B viral load and susceptibility in children treated with oseltamivir and zanamivir.　Pediatr Infect Dis J, 33:e168-e172, 2014.

59. Kakuya F, Okubo H, Fujiyasu H, Kurisawa MJ, Kinebuchi T.　Clinical effectiveness of baloxavir marboxil against influenza in three seasons.　Pediatr Int, 64:e15169, 2022.

60. The International Society for Influenza and other Respiratory Virus Disease.　Antiviral group.:Flu antiviral landscape.　https://www.isirv.org/site/index.php/special-interest-groups/antiviral-group-home.　Accessed at 2024/05/31.